24 Multi-drug resistant Mycobacterium tuberculosis strains are widespread and present a challenge 25 to effective treatment of this infection. The need for a low-cost and rapid detection method for clinically 26 relevant mutations in Mycobacterium tuberculosis (MTB) that confer multi-drug resistance is urgent, 27 particularly for developing countries. We report here a novel test that detects the majority of clinically 28 relevant mutations in the beta-subunit of the RNA polymerase (rpoB) gene that confer resistance to 29 rifampin (RIF), the treatment of choice for tuberculosis (TB 
Introduction:

41
The global incidence of drug resistant TB, particularly multi-drug resistant (MDR) and 42 extremely-drug resistant (XDR) strains, is a major worldwide issue. Rates of MDR TB have been 43 estimated to be 4.8% of the 9.8 million TB infections (42), but rates as high as 55% have been observed 44 for previously treated patients (4). TB can be effectively treated if properly identified (28-29). However, 45 delayed initiation of appropriate treatment in suspected MDR-TB cases is associated with excess 46 morbidity and nosocomial transmission (39). It has been determined that the main contributor to delay in 47 treatment is poor sensitivity of diagnostic tests (26) ; the average sensitivity of sputum microscopy is 48 <60% in immunocompetent patients and is lower in HIV infected cases. Frequent smear-negative disease 49 increases the difficulty with detecting HIV-associated TB as well (33). While mycobacterium culture is 50 much more sensitive, it has a very slow turnaround time of 2-8 weeks and is technically complex (33).
51
Nucleic acid amplification-based tests have improved detection sensitivity and time-to-result but 52
historically have been difficult to effectively implement (21, 30-32, 37-38). A recently described real-53 time PCR approach brings ease-of-use but at high cost (6). 54
To address the needs of bringing sensitive and specific diagnostic testing closer to the patient in 55 the developing world, we have designed a novel approach for the detection of Mycobacterium 56
Tuberculosis (MTB) and mutations within the rpoB gene that confer resistance to the first line drug, 57
rifampin. Described herein is the performance of the bench top version of the assay, termed TB ID/R. 58
Target DNA sequences within the rpoB gene are amplified using a novel method, blocked primer 59 mediated HDA (bpHDA) which utilizes the isothermal amplification method helicase-dependent 60 amplification (2) to exponentially amplify target DNA sequences coupled with blocked primer/ RNase H2 61 mediated target-specific "hot start" (10). In bpHDA, modified blocked primers are utilized, which are 62 constructed with a single ribonucleotide linkage 4 bases inserted upstream of a 3'-end block added to 63 prevent primer extension. Once blocked primers hybridize to complementary target sequences, 64 thermostable RNase H2 derived from Pyrococcus abyssi is activated, cleaving the ribonucleotide linkage 65
in the primer present in duplex DNA. The short segment of the primer 3'of the ribonucleotide 66 dissociates, liberating the block and creating a free 3'-hydroxyl which is now capable of primer extension.
67
RNase H2 used here has very little activity at temperatures below 40 0 C and is highly active at 65 0 C, the 68 temperature required for HDA to amplify target sequences optimally (10 
Materials and Methods
76
Capture probe design 77 A set of overlapping probes were designed covering the core region of the rpoB gene where the 78 majority of mutations that confer rifampin resistance occur and which is highly conserved in the 79
Mycobacterium tuberculosis complex ( Figure 1) . We designed the probe set to be perfectly matched to 80 the wild-type rpoB gene sequence of Mycobacterium tuberculosis (27, GenBank Accession #L27989).
81
DNA capture probes were designed using MeltCalc™ (36, 41) , which uses nearest neighbor calculations 82
to optimize discrimination of all potential mutations. Criteria were set for a Tm of 58-60 0 C under our 83 assay conditions of 825 mM monovalent cation. Higher Tm probes (68 0 C) were required for those 84 covering the 3'-end of the amplicon (probes 5.7 and 7.5), due to the presence of competing secondary 85 structure in the amplicon. Each probe was screened to maximize discrimination (delta Tm) of the major 86 rifampin resistance mutations that it was designed to detect.
88
Chip production 89 
90
Crystalline silicon wafers were coated with the polymer amino functional T-structure 91 polydimethyl siloxane (TSPS, United Chemical Technologies, Bristol, PA) and cured at 150 0 C for 24 92
hours. The TSPS coated wafer was further prepared as previously described (44) Inc.) was added to a final amount of 0.2X for each reaction and fluorescence was monitored using the LC 130 480 instrument (Roche). To determine amplification efficiency, the amount of input genomic DNA to the 131 amplification reaction was plotted vs. crossing time (time of amplification required to generate detectable 132 fluorescence signal) and fitted to a linear curve fit. The slope of the curve is used to calculate efficiency 133 as follows: 134
The natural log of the amount of genomic DNA was plotted against the natural log of crossing time to 136 determine the doubling rate (in minutes) as follows: 137 ln(copies gDNA) = kt + ln(crossing time), where k = doubling time 138
139
Chip assay and imaging 140
The assay was performed using chips immobilized in 96-well plates with flat, square bottom 141 wells (Whatman). 20μl of amplicon and 80ul of hybridization buffer (5xSSC, 5mg/mL alkaline treated 142 casein, 0.05% Tween-20, and 0.03% ProClin-300 preservative, 250 pM biotin-labeled reverse 143 complementary sequence for the hybridization control probe, (αΗC) were added and briefly mixed in the 144 well for each chip and then the plate was incubated for 6 minutes in an oven (Torrey Pines Scientific) set 145 at 95 0 C to denature the amplicon. After denaturation, the plate was immediately transferred into a second 146 hybridization oven set at 53 0 C for 10 minutes. After hybridization, the wells were then briefly washed 3 147 times (200μl each) with wash buffer A (0.1xSSC, 0.1%SDS) followed by 3 times (200μl each) with wash 148 buffer B (0.1xSSC, 0.01% Tween 20). After wash, 100μl of peroxidase-conjugated anti-biotin 149 monoclonal mouse antibody (Jackson ImmunoResearch Laboratory, Inc) in 75mM sodium citrate, 500 150 mM sodium chloride, 10% fetal bovine serum, 5 mg/ml alkaline treated casein, 0.5% ProClin300 151 preservative was added to the well and then incubated at room temperature for 10 minutes. The wells 152
were further briefly washed 3 times (200μl each) with wash buffer B at room temperature. Then, 100μl 153 of TMB substrate (BioFX/SurModics) was added and incubated at room temperature for 5 minutes. 154
Finally, the wells were rinsed twice with distilled water and methanol, respectively. The chips were dried 155 using compressed air and images were taken using a CCD camera controlled by μEye IDS imaging 156 development system.
ImageJ (National Institute of Health; http://imagej.nih.gov/ij/) was used to quantify the chip spot 159 signal intensity. A circle was placed in the spot around the edge and the average signal pixel intensity was 160 measured. The same circle was then dragged out to the neighboring non-spot area and the average pixel 161 intensity was measured to generate background pixel value. The adjusted average spot signal intensity 162 was obtained by subtracting the background from the reacted spot signal intensity. For each probe with 163 signal intensity >100 pixels, the result was determined to be wild-type. Those values were then averaged 164 to determine a mean wild-type signal. Any probe signal <50 was determined to cover a mutant allele. 
TB ID/R Analytical Performance
203
To detect mutations present within the region of the rpoB gene amplified here, we created a set of 204 overlapping probes with perfect complementary to wild-type Mycobacterium tuberculosis, arrayed onto a 205 modified silicon chip; if a mutation is present in the amplicon, hybridization signal will be dramatically 206 reduced or eliminated for the probe that is complementary to the mutated region. For those mutations that 207 are covered with two overlapping probes, both probes could be affected (Figure 1 ). To validate sensitivity 208 and specificity of the final array, a set of full-length, single-stranded templates was designed representing 209 >95% of all known mutations in the rpoB core sequence of M. tuberculosis (7-8, 12-13, 16, 20, 23-25, 34-210 35, 43). Each was tested with the TB ID/R assay and each chip image was captured using a CCD camera.
211
As is seen in Figure 3 , probe signals were visually unambiguous; the wild-type amplicon displayed clear 212
and balanced signal for all probes. For the target sequences with mutations in codons 509 to 531, 213 complete loss of signal was observed in the probes that cover the mutant allele. Significant, but not 214 complete, reduction in signal was observed for the various mutations in the 533 codon. For all of the 215 tested point mutations, a single probe lost signal except in the case of mutations within codons 516 and 216 518 which affected the two probes that overlap those alleles. One mutation, 508Gcc, could not be 217 discriminated with this probe set. 218
Due to the virtually binary response of the probes to mutations, visual discrimination is 219 straightforward: if a spot is missing or very faintly present then a mutation is present. However, the array 220 is still visually complex so image analysis was also investigated to generate an automated call. Probe 221 pixel intensities were determined from the CCD image, corrected for background, and plotted for each 222 tested sample (Figure 4) . CCD image analysis verified the visual interpretation of the assay performance; 223 all tested mutations except in codon 533 have signal drop-out (<10 pixels). Analysis of each mutant 224 sample reveals signal-to-noise ratio of >20 for the drop-outs, 5.2 for 533Gtg and 9.4 for 533cCg allowing 225 for unambiguous discrimination (Figure 4) . 226
Limit of detection was determined by titrating known quantities of purified, wild-type MTB 227 genomic DNA using the TB ID/R assay. To detect a single copy of genomic DNA, 40 minutes of 228 amplification time was required ( Figure 5 ). 229
Additionally, we determined reactivity with other mycobacterium species including within the 230 MTB complex ( 
Clinical Isolate Testing 238
To further verify this assay, we tested genomic DNA from clinical isolates for 11 wild-type and 239 25 RIF-resistant specimens (Table 2) . TB ID/R assay correctly classified 11/11 wild-type samples (100% 240 specific, 95% CI 67.9-100%) and 24/25 RIF-resistant samples (96.0%, 95% CI 77.7-98.7%) compared to 241 a reference method of rpoB gene sequencing. The wild-type amplicons displayed strong signal on each 242 probe with less than 2-fold variability across 11 unique isolates (data not shown). For each of the clinical 243 samples containing a single mutation, similar levels of discrimination as compared to results obtained 244 using synthetic templates were observed. Signal drop-out was observed for mutations in codons 511 to 245 526. Discrimination was not as good for the amplicon from genomic DNA for the S531L mutation as for 246 the synthetic template but was easily discriminated with signal-to-noise ratio of 19 as an average for three 247 unique strains. The L533P mutation performed similarly to the synthetic template with signal-to-noise of 248
249
The TB ID/R assay was further challenged with 8 clinical samples identified by rpoB gene 250 sequencing to contain multiple mutations in the rpoB core region. TB ID/R correctly classified 7/8 as 251 mutant. Unexpected probe response in a sample with H526N/ L533V (#15606) was observed, with signal 252 loss only observed with probe 7.5, when both probe 5.7 and 7.5 should have been affected. Sample 253 #11230 was correctly reported as mutant by TB ID/R, but with a very low ratio, 2.6. Sequencing of this 254 sample revealed a mixed base at the mutant position indicating the presence of two unique alleles present, 255 explaining the low ratio for this mutation. The mixed sample (#16866) that was discordant between the 256 TB ID/R assay and the initial rpoB gene sequencing was subject to repeat sequencing of the rpoB gene. 257 on January 10, 2018 by guest http://jcm.asm.org/
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Sample #16866 was mis-identified as wild-type by TB ID/R. Re-sequencing confirmed the initial 258 sequencing determination for the sample to be a mixed WT/H526Y result. 259
Discussion: 260
Herein, we have described a novel amplification method that adds a hot start component to the 261 isothermal amplification method, bpHDA, which permits more rapid amplification and potentially greater 262 level of multiplexing. By using this blocked primer approach, initiation of DNA amplification is DNA 263 target-dependent, improving sensitivity and specificity by mitigation of competing primer artifact 264 amplification. Analysis revealed a highly efficient exponential amplification system with rapid doubling 265 times suggesting initiation of HDA by RNase H2 mediated cleavage of blocked primers is rapid and not 266 rate limiting. Amplified products were detected using a silicon chip modified with a polymer coating to 267 create a surface with optical properties such that the surface-bound DNA hybrids transduce a permanent 268 change in color intensity on the chip surface visible to the unaided eye. Additionally, the surface is 269 molecularly flat and chemically inert, thereby reducing non-specific interactions allowing for highly 270 sensitive and specific detection. This allows for discrimination of SNPs as demonstrated here, and with 271 picomolar limits of detection, only short hybridization reactions are required with bpHDA amplified 272 target sequences to generate detectable surface-bound hybrids. Because the signal response to mutations 273 is effectively binary, results can be determined using either a non-instrumented visual approach or with an 274 inexpensive CCD or CMOS camera-based imaging system. 275
The analytical performance of TB ID/R is similar to other recently described molecular methods 276 for the detection of the M. tuberculosis complex strains including those with mutations in the rpoB gene 277 associated with RIF resistance. A comprehensive set of mutant templates was constructed based on a 278 survey of the literature (7-8, 12-13, 16, 20, 23-25, 34-35, 43 ), and all mutations tested herein were 279 discriminated with the exception of one, 508Gcc. Nearest neighbor analysis revealed that this probe set 280 was unable to discriminate this mutation (delta Tm = 0 0 C). Fortunately, this is a very rare mutation, 281 accounting for less than 0.1% of the reported rifampin resistance cases in TB. Alternative designs 282 including addition of secondary mutations in the probe or primer sequences are currently being tested to 283 improve discrimination of this mutation as well as codon 533, where the discrimination is also not binary.
284
Testing of genomic DNA isolated from clinical specimens displayed excellent sensitivity for the detection 285 of RIF-resistant strains and specificity for RIF-sensitive strains. Unlike other recently described molecular 286 diagnostic methods such as real-time PCR (13) and LAMP (17) with limited multiplex detection 287 capabilities, more information can be added to the TB ID/R assay to detect additional MTB resistance 288 mechanisms, potentially aiding in appropriate management and treatment of greater numbers of infected 289 patients, further reducing transmission risk. Diagnosis of MDR TB requires isoniazid (INH) resistance 290 information in addition to RIF resistance and mutations in the katG and inhA genes have been described 291 for detecting INH resistance (15), while XDR TB may be diagnosed by detecting mutations in gyrA and 292 gyrB genes for fluroquinolone resistance and the rrs gene for resistance to aminoglycosides in addition to 293 the RIF and INH mutations. These markers have been shown to detect XDR TB with high sensitivity 294 using another scalable test platform, reverse line blot hybridization assay (RLBH; 1, 3, 15). However, the 295 RLBH test is time-consuming and technically complex, limiting its usefulness in the point of care setting. 296
Multiple mutations within a sample, presumably from infections containing more than one TB 297 strain or from individual strains with multiple mutations, present potential challenges for genotypic 298 detection approaches. If two or more mutations exist within a single TB isolate, they are straightforward 299 to detect, but if there is a mixture of multiple unique RIF-resistant strains or mixtures of both RIF-300 resistant and RIF-sensitive populations, resistance detection could be complicated. To illustrate this 301 point, we tested two isolates that had a mixture of wild-type and mutant genomic templates (H526R/WT 302 and H526Y/WT) and obtained very different results. Both the H526R and H526Y mutations create a 303 signal drop-out for probe #5.7 in an isolate with a single mutation and thus, are strongly discriminated.
304
We detected the H526R/WT sample unambiguously indicating the assay is tolerant to the presence of 305 some amount of competing wild-type allele. However, the detection of the H526Y/WT as a wild-type 306 sample by TB ID/R, suggests that if the ratio of the wild-type allele is higher, the potential for missing a 307 mutation exists. Similarly, sample #15606 was correctly identified as a mutant sample, but not all of the 308 mutations were detected suggesting the source of the mutations was from more than one infecting 309 organism. In the case of the two samples with D516G/L533P mutants we were able to detect each 310 mutation with the same level of discrimination as if they were singly mutated isolates, suggesting that 311 they both occurred in the same organism. It has previously been observed in an assay with similar probe 312 design, that the strength of discrimination of a given mutation has a strong effect on the ability to detect 313 mutations in a mixed sample (5). This factor, combined with the fraction of each allele present, is critical 314 for correct detection in RIF-resistant samples containing more than one infecting organism. 315
The need for improved point-of-care testing for drug resistance in M. tuberculosis is acute.
316
Increasing the initial test sensitivity from 35% (microscopy sensitivity for HIV positive patient) to 95% 317 (molecular diagnostic approaches) would decrease the mean delay in diagnosis by approximately 25 days 318
and reduce the drop-out rate (infected individuals who cease seeking medical treatment) by approximately 319 30% (26) . By providing drug resistance information during the initial diagnostic test, the delay in 320 appropriateness of treatment, a critical factor in reducing attributable mortality for infectious diseases, 321 would further be reduced (22). To address the need for an easy-to-use, highly sensitive diagnostic test for 322 M. tuberculosis identification and drug susceptibility information, we are developing the TB ID/R test in 323 a disposable cartridge executed on a small, inexpensive, electromechanically simple, and potentially 324 battery-powered device. Automation of this test is being done in a manner that is consistent with the 325 ASSURED goals for developing world point of care testing for drug resistant TB (40). The combination 326 of isothermal amplification with chip-based, eye visible detection allows for the use of low cost heaters 327 and imaging equipment. Additionally, we are utilizing low cost, highly stable and robust reagents, with 328 measured stability at 37 0 C of 9 months so far with no loss in activity (data not shown). These reagents 329 have been used in commercially successful assays performed in the point-of-care setting for test-and-treat 330 indications such as viral and respiratory pathogens that require rapid, accurate results (11). Furthermore, 331 the chips can be produced on very large scale inexpensively utilizing well-established semi-conductor 332 processes (18). Early work with an appreciably similar device we are developing has shown excellent 333 performance for identifying staphylococcal species and the presence of the mecA gene in gram positive 334 cocci in cluster positive blood cultures from hospitalized patients (9). A low cost, easy-to-use device that 335 can detect RIF resistance could have a tremendous impact on reducing community spread of the disease 336 as well as improved outcomes for infected patients by providing appropriate treatment sooner. Intensity   1  WT128  508Gcc  509aCc  510caT  511cCg  511cGg  513cCa  513Gaa  513Aaa  513cTa  515Gtg  516gGc  516Tac  516gTc  518aTc  522tTg  522CAg  522tGg  526cCc  526Tac  526Gac  526caG  526Aac  526cGc  526cTc  529cAa  531tTg  531tGg  531Ccg  533cCg  533Gtg Mutation Mutation 
